Admission to Trading and First Day of Dealings

AI SummaryClose X

Coiled Therapeutics plc has been admitted to trading on AIM, formerly Roquefort Therapeutics plc, following the acquisition of a licence for AO-252 and a successful £8.5 million fundraising at 10 pence per share. The company is now a clinical-stage oncology firm focused on precision medicine, with its lead asset AO-252 showing promising early Phase I data in advanced solid tumours, including tumour reductions of up to 33% and a favourable safety profile. The capital raised will fund the expansion of the AO-252 Phase I trial into prostate and ovarian cancers, with data readouts anticipated by Q4 2026, and also supports the assessment of a STAT-6 siRNA programme for immunology.

Disclaimer*

UK 100

Latest directors dealings